title: Do cardiologists at a university hospital adopt the guidelines for the treatment of heart failure?
abstract: OBJECTIVE
  To verify whether the guidelines for the treatment of heart failure have been adopted at a university hospital. The guidelines recommend the following: use of angiotensin-converting enzyme inhibitors for all patients with systolic ventricular dysfunction, use of digitalis and diuretics for symptomatic patients, use of beta-blockers for patients in functional classes II or III, use of spironolactone for patients in functional classes III or IV.
  
  
  METHODS
  We analyzed the prescriptions of 199 patients. All these patients had ejection fraction (EF) </=0.50, their ages ranged from 25 to 86 years, and 142 were males. Cardiomyopathy was the most frequent diagnosis: 67 (33.6%) patients had dilated cardiomyopathy, 65 (32.6%) had ischemic cardiomyopathy.
  
  
  RESULTS
  Angiotensin-converting enzyme inhibitors were prescribed for 93% of the patients. 71.8% also had a prescription for digitalis, 86.9% for diuretics, 27.6% for spironolactone, 12% for beta-blockers, 37.2% for acetylsalicylic acid, 6.5% for calcium channel antagonists, and 12.5% for anticoagulants. In regard to vasodilators, 71% of the patients were using captopril (85.2mg/day), 20% enalapril (21.4mg/day), 3% hydralazine and nitrates. In 71.8% of the cases, the dosages prescribed were in accordance with those recommended in the large studies.
  
  
  CONCLUSIONS
  Most patients were prescribed the same doses as those recommended in the large studies. Brazilian patients tolerate well the doses recommended in the studies, and that not using these doses may be a consequence of the physician's fear of prescribing them and not of the patient's intolerance.
authors.affiliation: Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, 05403-000, Brazil. pereira.barreto@incor.usp.br
authors.forename: A C
authors.initials: AC
authors.lastname: Pereira Barretto
authors.forename: M R
authors.initials: MR
authors.lastname: Cucê Nobre
authors.forename: I
authors.initials: I
authors.lastname: Lancarotte
authors.forename: A R
authors.initials: AR
authors.lastname: Scipioni
authors.forename: J A
authors.initials: JA
authors.lastname: Franchini Ramires
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002303:Cardiac Output, Low / Q000188:drug therapy*; D002309:Cardiology / Q000592:standards*; D009202:Cardiomyopathies / Q000188:drug therapy; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D013318:Stroke Volume; D018754:Ventricular Dysfunction / Q000188:drug therapy
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors